Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

US Startup Funding Slows Sharply In March

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: US Startup Funding Slows Sharply In March Date: 2026-03-23 17:36 Source: https://news.crunchbase.com/business/us-startup-funding-slows-march-2026-data/ <p><span style="font-weight: 400;">After a rollicking start in </span><a href="https://news.crunchbase.com/ai/global-vc-investment-s…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A $110 billion funding round will likely take years, not weeks or months, to be topped

    60% confidence

  • This month's funding deceleration is mostly a U.S. phenomenon

    60% confidence

  • The slowdown is almost entirely due to fewer giant AI megarounds closing this month

    60% confidence

  • American companies raised just around $13 billion in seed through growth-stage funding in March 2026 so far

    60% confidence

  • US startup funding slowed dramatically in March 2026 after strong January and February

    60% confidence

  • European startup funding hit its highest point of the year in March 2026

    60% confidence

  • February's U.S. funding tally will remain one for the record books

    60% confidence

  • Early- and seed-stage dealmaking in March is on track to come in close to the prior two months' levels

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com